Ignite Creation Date:
2024-05-06 @ 7:19 PM
Last Modification Date:
2024-10-26 @ 3:05 PM
Study NCT ID:
NCT05978557
Status:
RECRUITING
Last Update Posted:
2023-08-21
First Post:
2023-07-28
Brief Title:
Brain Slice Explants to Predict Drug Response in Brain Tumors
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
UNC Lineberger Comprehensive Cancer Center
Study Overview
Official Title:
A Feasibility Study to Determine if a Novel Patient-derived Explant Platform Can Produce Drug Sensitivity Scores Within a Clinically Relevant Time Frame in Patients With CNS Tumors
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This biospecimen collection study will evaluate the feasibility of engrafting and testing resected Central nervous system CNS tumors tumor tissue ex vivo to estimate drug response in pediatric and adult subjects CNS tumors display remarkable heterogeneity and unfortunately there are no reliable precision oncology platforms that can identify the most effective therapy for each patient Recent work has demonstrated the success of functional precision oncology platforms using patient-derived explant PDE at predicting drug response in various cancers Since PDEs maintain important aspects of tumor heterogeneity they may prove effective as functional models for CNS tumors The purpose of this study is to explore the feasibility of using a novel PDE platform to generate drug sensitivity scores from patients with central nervous system tumors in Pediatric and adult subjects having low- or high-grade CNS tumors resected The secondary objective is to estimate the proportion of successfully scaled PDEs generated per given tumor size
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None